Patents Assigned to Cartela AB
  • Publication number: 20060178503
    Abstract: A recombinant or isolated integrin heterodimer comprising a novel subunit ?10 in association with a subunit ? is described. The ?10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of ?10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit ?10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.
    Type: Application
    Filed: February 6, 2006
    Publication date: August 10, 2006
    Applicant: Cartela AB
    Inventor: Evy Lundgren-Akerlund
  • Patent number: 7029858
    Abstract: A recombinant or isolated integrin heterodimer comprising a novel subunit ?10 in association with a subunit ? is described. The ?10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit ?10 can be used as marker or target of all types of cells, e.g. of chondrocytes, osteoblasts and fibroblasts. The integrin or subunit ?10 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: April 18, 2006
    Assignee: Cartela AB
    Inventor: Evy Lundgren-â„«kerlund
  • Publication number: 20050255182
    Abstract: An antigen indicative of the presence of atherosclerotic plaque is provided. The antigen is used in a method for slowing or arresting progression and/or effecting regression of atherosclerotic plaque in a mammal, comprising administering to the mammal a binding agent having binding sites specific for said antigen of said mammal. Also included are methods for diagnosing a mammal who has a risk of developing atherosclerosis, comprising determining the amount of said antigen. Moreover, uses of said antigen for detection and diagnosing atherosclerosis is provided.
    Type: Application
    Filed: June 16, 2003
    Publication date: November 17, 2005
    Applicant: Cartela AB
    Inventor: Evy Lundgren-Akerlund
  • Publication number: 20050221327
    Abstract: A marker for mesenchymal stem cells (MSC) is provided, comprising an integrin alpha 10 chain and/or an integrin alpha 11 chain expressed on the cell surface of or intracellular in a MSC. The marker is used in methods for identification of mammalian MSC and in methods for isolation of MSC. Also included are isolated cellular populations of mammalian MSC and a cellular composition comprising the latter. Moreover, uses of said marker for isolation, modulation and identification mammalian MSC are provided.
    Type: Application
    Filed: June 12, 2003
    Publication date: October 6, 2005
    Applicant: CARTELA AB
    Inventor: Evy Lundgren-Akerlund